School of Mathematics and Computing (Computational Science and Engineering), Yonsei University, Seoul, Korea.
School of Mathematics and Computing (Mathematics), Yonsei University, Seoul, Korea.
Yonsei Med J. 2023 Jun;64(6):366-374. doi: 10.3349/ymj.2022.0624.
The strategy of latent tuberculosis infection (LTBI) treatment in household tuberculosis (TB) contacts has been expanding in South Korea. However, there is little evidence of the cost-effectiveness of LTBI treatment in patients over 35 years of age. This study aimed to evaluate the cost-effectiveness of LTBI treatment among household TB contacts in different age groups in South Korea.
An age-structured model of TB was developed based on the reports from the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Quality-adjusted life-years (QALY) and the averted number of TB-related deaths were estimated along with discounted costs for a measure of incremental cost-effectiveness ratios.
The number of cumulative active TB cases would decrease by 1564 and 7450 under the scenario of LTBI treatment for those aged <35 years and <70 years, respectively, relative to the no-treatment scenario. The treatment strategies for patients aged 0 to <35 years, <55 years, <65 years, and <70 years would add 397, 1482, 3782, and 8491 QALYs at a cost of $660, $5930, $4560, and $2530, respectively, per QALY. For the averted TB-related deaths, LTBI treatment targeting those aged 0 to <35 years, <55 years, <65 years, and <70 years would avert 7, 89, 155, and 186 deaths at a cost of $35900, $99200, $111100, and $115700 per deaths, respectively, in 20 years.
The age-specific expansion policy of LTBI treatment not only for those under 35 years of age but also for those under 65 years of age among household contacts was cost-effective in terms of QALYs and averted TB deaths.
潜伏性结核感染(LTBI)治疗策略在韩国的家庭结核病(TB)接触者中不断扩大。然而,对于 35 岁以上患者的 LTBI 治疗成本效益证据较少。本研究旨在评估韩国不同年龄组家庭 TB 接触者中 LTBI 治疗的成本效益。
根据韩国疾病控制和预防机构以及国家健康保险服务的报告,建立了一个结核病年龄结构模型。沿着已贴现成本的增量成本效益比来估计质量调整生命年(QALY)和避免的结核病相关死亡人数。
与不治疗情景相比,LTBI 治疗方案可使<35 岁和<70 岁人群的累积活动性结核病病例分别减少 1564 例和 7450 例。0 至<35 岁、<55 岁、<65 岁和<70 岁患者的治疗策略将分别增加 397、1482、3782 和 8491 QALY,成本分别为 660、5930、4560 和 2530 美元/QALY。对于避免的结核病相关死亡,针对 0 至<35 岁、<55 岁、<65 岁和<70 岁人群的 LTBI 治疗方案可避免 7、89、155 和 186 例死亡,20 年内的成本分别为 35900、99200、111100 和 115700 美元/例。
对于家庭接触者,LTBI 治疗的年龄特异性扩展策略不仅对 35 岁以下人群,而且对 65 岁以下人群在 QALY 和避免结核病死亡方面都是具有成本效益的。